Teachers Advisors LLC Purchases 15,928 Shares of Endo International PLC (ENDP)
Teachers Advisors LLC increased its position in Endo International PLC (NASDAQ:ENDP) (TSE:ENL) by 1.9% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 840,470 shares of the company’s stock after acquiring an additional 15,928 shares during the quarter. Teachers Advisors LLC owned about 0.38% of Endo International PLC worth $9,388,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently made changes to their positions in ENDP. OppenheimerFunds Inc. raised its stake in Endo International PLC by 182.9% in the 1st quarter. OppenheimerFunds Inc. now owns 2,873,153 shares of the company’s stock valued at $32,065,000 after acquiring an additional 1,857,678 shares during the period. Bank of New York Mellon Corp lifted its holdings in Endo International PLC by 38.7% during the first quarter. Bank of New York Mellon Corp now owns 2,271,111 shares of the company’s stock valued at $25,345,000 after purchasing an additional 633,904 shares during the last quarter. Schneider Capital Management Corp boosted its position in Endo International PLC by 14.9% during the first quarter. Schneider Capital Management Corp now owns 642,311 shares of the company’s stock worth $7,168,000 after purchasing an additional 83,100 shares during the period. Canada Pension Plan Investment Board boosted its position in Endo International PLC by 93.4% during the second quarter. Canada Pension Plan Investment Board now owns 565,240 shares of the company’s stock worth $6,314,000 after purchasing an additional 273,024 shares during the period. Finally, Ameriprise Financial Inc. boosted its position in Endo International PLC by 685.0% during the first quarter. Ameriprise Financial Inc. now owns 554,138 shares of the company’s stock worth $6,185,000 after purchasing an additional 483,545 shares during the period. 90.71% of the stock is owned by institutional investors.
In other Endo International PLC news, CEO Paul Campanelli purchased 6,500 shares of the stock in a transaction that occurred on Monday, August 14th. The shares were bought at an average cost of $7.71 per share, with a total value of $50,115.00. Following the acquisition, the chief executive officer now owns 213,620 shares in the company, valued at $1,647,010.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Terrance J. Coughlin purchased 20,000 shares of the stock in a transaction that occurred on Thursday, August 10th. The stock was acquired at an average cost of $7.70 per share, for a total transaction of $154,000.00. Following the completion of the acquisition, the chief operating officer now owns 181,369 shares in the company, valued at approximately $1,396,541.30. The disclosure for this purchase can be found here. Insiders have purchased 36,000 shares of company stock valued at $279,460 in the last quarter. 0.50% of the stock is currently owned by company insiders.
Several research firms have recently weighed in on ENDP. Canaccord Genuity set a $12.00 target price on shares of Endo International PLC and gave the stock a “hold” rating in a research note on Thursday, June 8th. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Endo International PLC in a research report on Thursday, June 8th. Stifel Nicolaus cut shares of Endo International PLC from a “buy” rating to a “hold” rating and dropped their price target for the company from $22.00 to $15.00 in a research note on Friday, June 9th. Royal Bank Of Canada set a $15.00 price target on shares of Endo International PLC and gave the company a “hold” rating in a research note on Monday, June 12th. Finally, William Blair reaffirmed a “market perform” rating on shares of Endo International PLC in a report on Wednesday, June 14th. Three equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and five have given a buy rating to the stock. Endo International PLC has an average rating of “Hold” and a consensus price target of $12.80.
Shares of Endo International PLC (ENDP) opened at 8.71 on Wednesday. Endo International PLC has a 52-week low of $7.41 and a 52-week high of $21.87. The stock’s market cap is $1.94 billion. The stock’s 50 day moving average is $8.67 and its 200 day moving average is $10.65.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings data on Tuesday, August 8th. The company reported $0.93 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.19. The firm had revenue of $875.73 million during the quarter, compared to analyst estimates of $832.66 million. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. The business’s quarterly revenue was down 4.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.86 earnings per share. Equities research analysts forecast that Endo International PLC will post $3.52 earnings per share for the current year.
Endo International PLC Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Want to see what other hedge funds are holding ENDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Endo International PLC (NASDAQ:ENDP) (TSE:ENL).
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.